ArticleScientific reports2026
Oncogenic and immunological roles of NSUN2 in triple negative breast cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Immunotherapy have led to clinical remissions in many solid tumors. However, the efficacy of immunotherapeutic monotherapy in triple-negative breast cancer (TNBC) is not very satisfactory. NSUN2 functions as a proto-oncogene in various cancers, promoting tumor cell proliferation, invasion, and metastasis. However, its role in modulating the tumor immune microenvironment, particularly in TNBC immunotherapy and its relationship with treatment sensitivity in TNBC remain to be further explored. In this study, we found that NSUN2 was highly expressed in pan-cancer, and elevated levels correlate with poor prognosis in TNBC. Furthermore, NSUN2 expression demonstrated a positive correlation with immune cell infiltration and the expression of immune checkpoint molecules. Up-regulated NSUN2 expression lowers the sensitivity of many chemotherapy drugs, and higher the sensitivity of many molecular-targeted agents. Functionally, depleted NSUN2 inhibits the proliferation and migration of TNBC cells significantly. Our study reveals the critical role of NSUN2 in regulating the immune microenvironment of TNBC, provides a theoretical foundation for its potential as a novel immunotherapy target, addresses the knowledge gap regarding NSUN2's immunoregulatory mechanisms in TNBC, and demonstrates significant clinical translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.